Dexcom Inc (DXCM) Stock Price & Analysis
Dexcom Inc (DXCM) rose 2.05% to USD 78.19 as of June 9, 2026 at 22:40 UTC, according to Nexqual real-time market data.
DXCM last closed at USD 76.62; the session ranged USD 76.5–78.82 on volume of 4,759,939 shares. Market capitalization is $30.17B, with a 52-week range of USD 54.11–89.98 (NMS). Source: Nexqual, June 9, 2026 at 22:40 UTC.
Key Statistics (as of June 9, 2026 at 22:40 UTC)
| Price | USD 78.19 |
|---|---|
| Change | ▲ 2.05% (up) |
| Previous Close | USD 76.62 |
| Open | USD 77.48 |
| Day Range | USD 76.5 – 78.82 |
| 52-Week Range | USD 54.11 – 89.98 |
| Volume | 4,759,939 shares |
| Market Cap | $30.17B |
| Exchange | NMS |
Technical Analysis (DXCM)
Nexqual's technical model rates DXCM "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 22:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 71.9 (overbought) |
| vs SMA50 | Above (USD 65.1) |
| MACD | 3.37 (positive) |
Analyst Ratings (DXCM)
Wall Street analysts rate DXCM "Strong Buy" based on 24 analysts, with a mean price target of USD 83 (range USD 65–112), per Nexqual as of June 9, 2026 at 22:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 83 |
| High Target | USD 112 |
| Low Target | USD 65 |
| Buy / Hold / Sell | 24 / 3 / 0 |
Earnings (DXCM)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.61 |
| Revenue Estimate | $1.29B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.56 vs est 0.47 ▲ beat |
| 2025-12-31 | USD 0.68 vs est 0.65 ▲ beat |
| 2025-09-30 | USD 0.61 vs est 0.57 ▲ beat |
| 2025-06-30 | USD 0.48 vs est 0.44 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financials & Fundamentals (DXCM)
| Total Revenue | $4.82B |
|---|---|
| Revenue Growth (YoY) | +15.00% |
| Gross Margin | +61.50% |
| Operating Margin | +21.42% |
| Profit Margin | +19.31% |
| ROE | +35.62% |
| Debt / Equity | 46.83 |
| Current Ratio | 1.95 |
| Total Cash | $2.42B |
| Total Debt | $1.38B |
| Free Cash Flow | $1.06B |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financial Health Score (DXCM)
Nexqual rates Dexcom Inc's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 22:40 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 62%, operating 21% |
| Balance Sheet | Solid — $2.42B cash vs $1.38B debt, net cash position |
| Cash Flow | Strong — FCF $1.06B, 23% margin |
| Efficiency | Strong — ROE 36%, ROA 9.7% |
Ownership (DXCM)
| Insider Ownership | +0.28% |
|---|---|
| Institutional Ownership | +102.70% |
| Shares Outstanding | 385.87M |
| Float | 384.41M |
| Short % of Float | +5.24% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Leadership (DXCM)
Dexcom Inc is led by Jacob Steven Leach (age 47), President, CEO & Director, per Nexqual as of June 9, 2026 at 22:40 UTC.
| President, CEO & Director | Jacob Steven Leach (age 47) |
|---|---|
| Executive Chairman of the Board | Kevin Ronald Sayer (age 67) |
| Executive VP, CFO & Chief Accounting Officer | Jereme M. Sylvain (age 45) |
| Executive VP & CTO | Peter Simpson |
| Vice President of Finance and Investor Relations | Sean Christensen |
Major Backers & Investors (DXCM)
Notable institutional backers of Dexcom Inc include Baillie Gifford, Alliancebernstein L.P., UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, according to Nexqual as of June 9, 2026 at 22:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baillie Gifford | 4.04% |
| Alliancebernstein L.P. | 3.35% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.53% |
| Wellington Management | 2.42% |
| Invesco | 2.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.54% |
| BlackRock | 11.39% |
| State Street | 5.84% |
| Geode Capital | 3.2% |
| Amundi | 1.64% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
From Dexcom Inc's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
- The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
- It markets its products directly to endocrinologists, physicians, and diabetes educators.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
| IDXX | IDEXX Laboratories, Inc. | USD 578.89 | ▲ 2.98% |
| ALGN | Align Technology, Inc. | USD 178.1 | ▲ 6.18% |
| VEEV | Veeva Systems Inc. | USD 167.68 | ▼ 2.86% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 445.77 | ▼ 0.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:40 UTC. This page is informational and not investment advice.